Evidence map›Paper›PMID 32581010›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2020

Blanca L Valle, Sebastian Rodriguez-Torres, Elisabetta Kuhn, Teresa Díaz-Montes, Edgardo Parrilla-Castellar, Fahcina P Lawson, Oluwasina Folawiyo, Carmen Ili-Gangas, Priscilla Brebi-Mieville, James R Eshleman and 4 more

Open access · greenAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Blanca L ValleOtolaryngology Department, Head and Neck Cancer Research Division, The Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Sebastian Rodriguez-TorresDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.ORCID 0000-0003-1264-0497
Elisabetta KuhnDivision of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Italy.
Teresa Díaz-MontesThe Lya Segall Ovarian Cancer Institute, Mercy Medical Center, Baltimore, Maryland.
Edgardo Parrilla-CastellarDepartment of Pathology, University of Washington, Seattle, Washington.
Fahcina P LawsonOtolaryngology Department, Head and Neck Cancer Research Division, The Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Oluwasina FolawiyoOtolaryngology Department, Head and Neck Cancer Research Division, The Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Carmen Ili-GangasLaboratory Integrative Biology (LIBi), Center for Excellence in Translational Medicine-Scientific and Technological Bioresources Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco, Chile.ORCID 0000-0002-4009-4406
Priscilla Brebi-MievilleLaboratory Integrative Biology (LIBi), Center for Excellence in Translational Medicine-Scientific and Technological Bioresources Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco, Chile.
James R EshlemanDepartment of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland.
James HermanDepartment of Medicine, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania.
Ie-Ming ShihDivision of Pathology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Department of Biomedical, Surgical, and Dental Sciences, University of Milan, Italy.
David SidranskyOtolaryngology Department, Head and Neck Cancer Research Division, The Johns Hopkins University, School of Medicine, Baltimore, Maryland.
Rafael Guerrero-PrestonOtolaryngology Department, Head and Neck Cancer Research Division, The Johns Hopkins University, School of Medicine, Baltimore, Maryland. rafael.guerrero@upr.edu.
Johns Hopkins University · USUniversidad de La Frontera · CLHarvard University · USMercy Medical Center · USMetLife (United States) · USUniversity of Milan · ITUniversity of Pittsburgh · USUniversity of Washington · US

Funding

INTEGRATED DEVELOPMENT OF NOVEL MOLECULAR MARKERSU01CA084986 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 1999 to 2014
$33.8M
SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Stephanie Gaillard · 2018 to 2026
$20.5M
Precision methylation biomarkers linked to cancer disparitiesR44MD014911 · NIMHD · LIFEGENE-BIOMARKS, INC. · PI GUERRERO-PRESTON, RAFAEL · 2019 to 2021
$1.7M
Epigenomic Markers of HNSCC Survival Across Ethnic GroupsK01CA164092 · NCI · JOHNS HOPKINS UNIVERSITY · PI GUERRERO-PRESTON, RAFAEL · 2011 to 2014
$530k
NCI NIH HHS K01 CA164092NCI NIH HHS P50 CA228991NCI NIH HHS U01 CA084986NIMHD NIH HHS R44 MD014911
6 · The paper itself

Abstract

Molecular alterations that contribute to long-term (LT) and short-term (ST) survival in ovarian high-grade serous carcinoma (HGSC) may be used as precision medicine biomarkers. DNA promoter methylation is an early event in tumorigenesis, which can be detected in blood and urine, making it a feasible companion biomarker to somatic mutations for early detection and targeted treatment workflows. We compared the methylation profile in 12 HGSC tissue samples to 30 fallopian tube epithelium samples, using the Infinium Human Methylation 450K Array. We also used 450K methylation arrays to compare methylation among HGSCs long-term survivors (more than 5 years) and short-term survivors (less than 3 years). We verified the array results using bisulfite sequencing and methylation-specific PCR (qMSP). in another cohort of HGSC patient samples (

Indexed as

Adaptor Proteins, Signal TransducingBiomarkers, TumorCell Line, TumorCohort StudiesCystadenocarcinoma, SerousDecitabineDNA MethylationDown-RegulationEpitheliumFallopian TubesFemaleGene Expression Regulation, NeoplasticGuanylate KinasesHistonesHumansHydroxamic AcidsAdaptor Proteins, Signal TransducingBiomarkers, TumorDecitabineGuanylate KinasesH2BC3 protein, humanHistonesHydroxamic AcidsMAGI2 protein, humantrichostatin A

Identifiers

PMID32581010
PMCPMC8082233
OpenAlexW3037973164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.